


# Tumor reactivity for patients treated with Nivolumab and Bevacizumab for recurrent Glioblastoma

Maarup S<sup>1,3</sup>, Skadborg SK<sup>2</sup>, Draghi A<sup>3</sup>, Hasselbalch B<sup>1</sup>, Svane IM<sup>3</sup>, Law I<sup>4</sup>, Skjoeth-Rasmussen J<sup>5</sup>, Scheie D<sup>6</sup>, Østrup O<sup>7</sup>, Poulsen HS<sup>1</sup>, Hadrup SR<sup>2</sup>, Lassen U<sup>1</sup>

1 The Brain Tumor Center, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 København Ø  
2 Department of Health Technology, Kemitorvet, Building 204, 2800 Kongens Lyngby  
3 National Center for Cancer Immune Therapy, CCIT, Herlev Hospital, Herlev Ringvej 75, 2730 Herlev  
4 Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Blegdamsvej 9, 2100 København Ø  
5 Department of Neurosurgery, Rigshospitalet, Blegdamsvej 9, 2100 København Ø  
6 Department of Pathology, Rigshospitalet, Blegdamsvej 9, 2100 København Ø  
7 Department of Genomic Medicine, Kennedy Center, Rigshospitalet Glostrup, Gamle Landevej 7, 2600 Glostrup

## Tumor reactivity after Nivolumab



### Abstract

#### Introduction:

Glioblastoma multiforme (GBM) is an aggressive brain tumor with a poor prognosis. Receiving the standard of care, the median survival is 14.6 months [1]. We have no standard treatment for relapse and known options have limited effect. Novel treatments are necessary to improve survival and especially quality of life.

#### Methods:

We present our translational study; a phase II open label, two-armed translational study of Nivolumab and Bevacizumab for recurrent GBM, who have failed Stupp's regime [1]. Patients are included in two arms depending on the possibility of salvage neurosurgical resection. Both arms receive Nivolumab and Bevacizumab administered every second weekend, and the surgical arm also receive Nivolumab 7 days prior surgery in order to obtain post-surgical specimens for analysis. Forty-four patients were included by January 2021; 20 in each arm (four screen-failures). In the surgical arm, 20 fresh tumor samples as well as paired tissue from primary tumor were available. Tumor infiltrating lymphocytes (TILs) and tumor digest were produced in vitro from recurrent settings. Young TILs were expanded from fresh tumor fragments after minimal-culture, whereas rapidly expanded TILs (REP TILs) were obtained after massive expansion [2].


#### Results:

We investigated by intracellular cytokine staining the TIL reactivity after exposure to autologous tumor digest in order to evaluate whether the TILs were tumor-reactive or bystanders. Material from 19 patients was analyzed (one out of the 20 collected biopsies was limited in size, and no tumor digest could be produced). Four out of 19 TIL samples showed tumor reactivity after exposure to the autologous tumor digest. Though meaning that 15 patients showed no tumor reactivity. Tumor reactivity was ranged between 2 to x% in CD8+ TILs and from 10 to x% in CD4+ TILs. Tumor reactivity data from the surgical arm will be further analyzed in relation with the available WES and RNAseq data from biopsies collected before and after Nivolumab. However, these analyses are pending.

#### References:

1. Stupp R et al.: Lancet Oncol 2009, 10(5): 459-466
2. Donia M, Junker N, Ellebaek E, Andersen MH, Straten PT, Svane IM. Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution. Scand J Immunol. 2012;75(2):157-67.

### 40 Recurrent GBMs



### Material and Methods

An Open-Label, Phase II, two armed study of Nivolumab and Bevacizumab for recurrent GMB after Stupp's regime

(2 Gy x 30 plus concomitant and adjuvant temozolomide [1]);

- Patients: 40 patients with recurrent GBM;
  - Arm A: Salvage re-resection possible
  - Arm B: Salvage re-resection not possible
- Samples: PBMC (Peripheral Blood Mononuclear Cell), TILs (Tumor Infiltrating Lymphocytes), tumordigest.
- Investigate biomarkers, TMB (tumor mutation burden) and neoepitope load
- WES (mutations, mutational load), RNA seq (fusion, alternative splicing), expression array (subtyping: neural, mesenchymal, classical) and CytoScan HD (somatic copy number alterations)
- T-cell reactivity analysed by interleukin-measuring, Olink

### Recruitment

- 1 site; Rigshospitalet, Copenhagen
- Enrollment; October 2018 – January 2021
- Total of 40 patients:
  - Arm A: Salvage re-resection possible
  - Arm B: Salvage re-resection not possible

#### Acknowledgements

- The patients and their families
- The clinicians and lab-technicians
- The study is funded by the Danish Cancer Society, Arvid Nilssons Foundation and Dr. Sofus Carl Emil Friis and Wife Olga Friis' Foundation
- Nivolumab is sponsored by Bristol-Myers-Squibb

The study is approved by the National Committee on Health Research Ethics

ClinicalTrials.gov Identifier: NCT03890952  
PI: Ulrik Lassen, Professor  
SI: Benedikte Hasselbalch, MD, PhD

